[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601218":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with malignant tumors of the gastrointestinal tract","EXPERIMENTAL",null,[13],"Drug: Technetium [99mTc]-H7ND injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Technetium [99mTc]-H7ND injection","Technetium \\[99mTc\\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Hongcheng Shi","CONTACT","021-64041990","shi.hongcheng@zs-hospital.sh.cn",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":11,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Zhongshan Hospital Affiliated to Fudan University","RECRUITING","Shanghai","China","CN",{"type":34,"coordinates":35},"Point",[36,37],121.45806,31.22222,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601218","phase-2-a-phase-ii-clinical-study-to-evaluate-the-efficacy-and-safety-of-technetium-99mtc-h7nd-injection-in-the-diagnosis-of-peritoneal-metastasis-of-gastrointestinal-malignant-tumor-100601218",false,"NCT07107633","A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.","A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.","Inclusion Criteria:\n\nOnly those who meet all the following requirements are eligible to join the group:\n\n1. Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;\n2. Subjects with gastrointestinal malignant tumor confirmed by histology\u002Fcytology;\n3. Subjects to be surgically removed or explored;\n4. The estimated survival time is ≥12 weeks;\n5. Subjects of childbearing age agreed to adopt effective contraceptive measures during the study period;\n6. Subjects fully understand the purpose, nature, methods and possible adverse reactions of the experiment, voluntarily participate in and sign a written informed consent, and are willing to follow the requirements of the protocol to complete the study.riteria:\n\nThose who meet one of the following items are not allowed to join the group:\n\n1. According to the researcher's judgment, during the screening period, from the imaging examination to the comprehensive real diagnosis information result, the patients were treated with anti-digestive tract tumor;\n2. symptomatic brain metastases who need treatment;\n3. Have serious cardiovascular and cerebrovascular diseases;\n4. There are other contraindications for imaging examination of the research plan, such as claustrophobia;\n5. Have a history of other malignant tumors;\n6. Pregnant (pregnancy test positive in screening period) or lactating women;\n7. Other circumstances that the researcher considers inappropriate to participate in this clinical trial.","ALL","18 Years",{"count":53,"type":54},90,"ESTIMATED","INTERVENTIONAL",[57],"PHASE2","The main purpose of this study is to evaluate the effectiveness of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \\[99mTc\\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.",[60,61],"Solid Tumor","Peritoneal Metastasis","2025-08-04",{"date":64,"type":65},"2025-08-06","ACTUAL",{"date":67,"type":65},"2025-03-12",{"date":69,"type":54},"2025-09",{"name":5,"class":6},1]